Sinobiopharma, Inc. Appoints New Chief Financial Officer and Director to the Board
September 29 2009 - 11:00PM
PR Newswire (US)
NANTONG CITY, China, Sept. 29 /PRNewswire-Asia-FirstCall/ --
Sinobiopharma, Inc. (OTC:SNBP) (BULLETIN BOARD: SNBP)
('Sinobiopharma' or, the 'Company') is pleased to announce that it
has appointed Mr. Xinjie (James) Mu as the new Chief Financial
Officer and as a director on the Board. Dr. Lequn Huang resigned as
the Chief Financial Officer in order to make room for the
appointment of Mr. Mu. Mr. Mu has more than twelve years experience
in the financial field. Most recently, Mr. Mu has been an
independent consultant working for China based US public companies.
Prior to that, he was a Chief Financial Officer at Jingwei
International Limited (OTCBB: JNGW.OB). Prior to that, he served as
a senior accountant at Geller and Company in New York City. Mr. Mu
is also a Director of China Infrastructure Investment Corporation
(NASDAQ:CIIC) since March 2008. Fluent in Mandarin and English, Mr.
Mu holds a Bachelor of Science degree from Hebei University of
Science and Technology, and a Master of Business Administration
from Baruch College at the City University of New York. 'We are
greatly pleased to have Mr. Mu join the Company and we are sure
that his professional background and strong management skills will
add tremendous value to Sinobiopharma's future endeavors,' stated
Dr. Lequan Huang, President and CEO of Sinobiopharma. Separately,
the Company announces that Mr. Martin Shen resigned as director of
the Board for personal reasons. 'On behalf of the Board of
Directors and Sinobiopharma, I want to personally thank Mr. Shen
for his contributions to the Company and wish him well,' said Dr.
Lequn Huang, President and CEO of Sinobiopharma. About
Sinobiopharma Sinobiopharma Inc. is a fully integrated and highly
innovative biopharmaceutical company engaged in the research and
development, manufacture and marketing of biopharmaceutical
products in China, the world's fastest growing pharmaceutical
market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in
China, the Company's current therapeutic focus is on
anesthesia-assisted agents and cardiovascular drugs. FORWARD
LOOKING STATEMENTS This news release may include "forward-looking
statements" regarding Sinobiopharma, Inc., and its subsidiaries,
business and project plans. Such forward looking statements are
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and section 21E of the United States Securities and
Exchange Act of 1934, as amended, and are intended to be covered by
the safe harbor created by such sections. Where Sinobiopharma, Inc.
expresses or implies an expectation or belief as to future events
or results, such expectation or belief is believed to have a
reasonable basis. However, forward-looking statements are subject
to risks, uncertainties and other factors, which could cause actual
results to differ materially from future results expressed,
projected or implied by such forward-looking statements.
Sinobiopharma, Inc. does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
DATASOURCE: Sinobiopharma, Inc. CONTACT: Sinobiopharma, Inc.,
Investor Relations, +1-877-568-0188
Copyright